Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study

Sodium‐glucose cotransporter type 2 inhibitors (SGLT‐2i) represent a unique class of anti‐hyperglycaemic agents for type 2 diabetes mellitus that selectively inhibit renal glucose reabsorption, thereby increasing urinary excretion of glucose. Several studies have demonstrated the cardioprotective effects of SGLT‐2i in patients with heart failure (HF), unrelated to its glucosuric effect. It is unclear whether the benefits of SGLT‐2i therapy also rely on the improvement of left ventricular (LV) and/or right ventricular (RV) function in patients with HF. This study aimed to evaluate the effect of SGLT‐2i on LV and RV function through conventional and advanced echocardiographic parameters with a special focus on RV function in patients with HF.

• Publication year

  2023

• Venue

  ESC Heart Failure

• Publication date

  2023-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ehf2.14331PMID 36924023PMCID 10192273
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study

  2023cited by this paper
• Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.

  2022cited by this paper
• Association of Left Atrial Structure and Function With Heart Failure in Older Adults.

  2022cited by this paper
• Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients

  2021cited by this paper
• Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction

  2021cited by this paper
• Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?

  2021cited by this paper
• New Targets in Heart Failure Drug Therapy

  2021cited by this paper
• Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.

  2021influential reference
• Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.

  2021cited by this paper
• 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

  2021cited by this paper
• Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure

  2021cited by this paper
• Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction

  2020cited by this paper
• Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial

  2020cited by this paper
• A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial

  2020influential reference
• Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction

  2020cited by this paper
• Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

  2020cited by this paper
• Randomized Trial of Empagliflozin in Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction.

  2020cited by this paper
• Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans

  2020cited by this paper
• The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes

  2019cited by this paper
• Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

  2019cited by this paper
• Left atrium: a forgotten biomarker and a potential target in cardiovascular medicine.

  2019cited by this paper
• Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry

  2019cited by this paper
• SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

  2019cited by this paper
• Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload

  2019cited by this paper
• Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction

  2019cited by this paper
• Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients

  2019cited by this paper
• Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.

  2019cited by this paper
• Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

  2018cited by this paper
• Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?

  2018cited by this paper
• A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.

  2018cited by this paper
• The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

  2018cited by this paper
• Global Public Health Burden of Heart Failure.

  2016cited by this paper
• Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

  2016cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

  2015cited by this paper
• An alternative echocardiographic method to estimate mean pulmonary artery pressure: diagnostic and clinical implications.

  2009cited by this paper
• A simple method for noninvasive estimation of pulmonary vascular resistance.

  2003cited by this paper

• The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

  2024influential citation
• Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study

  2023cites this paper
• Switch to gliflozins and biventricular function improvement in patients with chronic heart failure and diabetes mellitus

  2023cites this paper